Lumos' oral growth hormone drug falls short of Novo's injectable incumbent at interim analysis

Lumos Pharma’s oral treatment for moderate pediatric growth hormone deficiency has failed to match up to Novo Nordisk’s injected drug Norditropin at the interim analysis of a phase 2 trial. But with growth in the Norditropin arm exceeding expectations, Lumos has pinned the blame on baseline imbalances.